After reporting stellar data at ASH, Terns is acquired for $6.7bn.
ApexOnco Front Page
Recent articles
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
Circle Pharma and Verismo feature in coveted sessions.
Projects from Chia Tai and Kestrel enter phase 1, along with a bispecific Kelun ADC.
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
